BioCentury
ARTICLE | Politics & Policy

C-PATH, MS Society form consortium to evaluate MS endpoints

December 7, 2012 2:20 AM UTC

The Critical Path Institute (C-Path) and the National Multiple Sclerosis Society launched the Multiple Sclerosis Outcome Assessments Consortium to develop new standards for assessing outcomes in clinical trials of MS therapies. The society said the consortium will collect, standardize and analyze data from MS studies and evaluate whether additional clinical measures can improve the sensitivity of the MS Functional Composite (MSFC) measure for predicting clinical benefit. The goal is to qualify as a primary endpoint for future trials a new clinical-reported outcome measure of disability. The consortium, which will obtain trial data from companies and other stakeholders, will include industry, academia and patient representatives, as well as regulatory agencies including FDA. The society said details are being finalized. ...